Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 175.00 | |
5 mg | In stock | $ 372.00 | |
10 mg | In stock | $ 556.00 | |
25 mg | In stock | $ 896.00 | |
50 mg | In stock | $ 1,220.00 | |
100 mg | In stock | $ 1,650.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 559.00 |
Description | Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2. |
In vitro | Tarloxotinib bromide is metabolized efficiently under hypoxia using a panel of human NSCLC cell lines (rate of TKI release 0.4-2.1 nM/hr/106 cells), a process that is inhibited by oxygen (TKI release <0.002 nM/hr/106 cells). Cellular anti-proliferative and receptor phosphorylation assays demonstrate a 14-80 fold reduction of Tarloxotinib bromide activity relative to TKI. Using PC9 tumors, hyperbaric oxygen breathing suppresse release of TKI from Tarloxotinib bromide by >80% (538 vs 99 nM/kg; p<0.01) compared to air breathing controls[1]. |
In vivo | Tarloxotinib bromide treatment regresses the WT EGFR NSCLC tumor models H125 and H1648, demonstrating Tarloxotinib bromide provides the necessary therapeutic index to inhibit WT EGFR in vivo[2]. |
Synonyms | TH-4000 |
Molecular Weight | 681.77 |
Formula | C24H24Br2ClN9O3 |
CAS No. | 1636180-98-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33 mg/mL (48.40 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tarloxotinib bromide 1636180-98-7 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HER Epidermal growth factor receptor Inhibitor ErbB-1 Tarloxotinib HER1 TH 4000 inhibit Tarloxotinib Bromide TH4000 TH-4000 inhibitor